CA
NZ
UK
AU
IND
US
…
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Ginkgo Bioworks programs cells and operates a biological engineering platform and foundry serving biotech, industrial, agricultural and government customers. Long-term growth may be supported by broader adoption of its cell-programming platform, recurring partner and service contracts, and rising demand for biologics, industrial biotech and biosecurity, and the company appears positioned to scale using data-driven automation.
Material risks include persistent operating losses and cash burn that could require dilutive financing, execution and scale-up challenges for complex laboratory operations, and regulatory, safety or public-perception constraints on engineered organisms.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -313.60M | -547.51M | -892.94M | -2121.40M | -1838.12M |
| Minority interest | - | 0.00M | -2.39M | 1.44M | -6.59M |
| Net income | -312.76M | -547.03M | -892.87M | -2106.37M | -1836.64M |
| Selling general administrative | 183.29M | 246.16M | 385.02M | 1429.80M | 862.95M |
| Selling and marketing expenses | - | - | 95.97M | - | - |
| Gross profit | 138.63M | 188.49M | 197.45M | 273.49M | 184.15M |
| Reconciled depreciation | 58.99M | 63.02M | 75.21M | 44.42M | 29.08M |
| Ebit | -313.60M | -547.41M | -892.85M | -2208.95M | -1828.47M |
| Ebitda | -254.61M | -484.39M | -821.29M | -2180.39M | -1877.57M |
| Depreciation and amortization | 58.99M | 63.02M | 71.55M | 28.56M | -49.10M |
| Non operating income net other | - | - | - | 87.55M | - |
| Operating income | -315.28M | -559.76M | -864.41M | -2208.95M | -1828.47M |
| Other operating expenses | 485.43M | 786.80M | 1115.86M | 2686.66M | 2142.30M |
| Interest expense | 0.00M | 0.09M | 0.09M | 0.11M | 2.37M |
| Tax provision | -0.84M | -0.48M | -14.64M | -15.03M | -1.48M |
| Interest income | 22.62M | 38.61M | 57.22M | 20.26M | 0.84M |
| Net interest income | 22.62M | 38.52M | 55.25M | 20.16M | -1.54M |
| Income tax expense | -0.84M | -0.48M | -0.07M | -15.03M | -1.48M |
| Total revenue | 170.16M | 227.04M | 251.46M | 477.71M | 313.84M |
| Total operating expenses | 453.91M | 748.25M | 1061.86M | 2482.44M | 2012.61M |
| Cost of revenue | 31.52M | 38.55M | 54.01M | 204.22M | 129.69M |
| Total other income expense net | 1.68M | 12.25M | -28.53M | 87.55M | -9.65M |
| Net income from continuing ops | -312.76M | -547.03M | -854.25M | -2106.37M | -1836.64M |
| Net income applicable to common shares | -312.76M | -547.03M | -892.87M | -2104.93M | -1830.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1119.70M | 1377.45M | 1665.34M | 2539.32M | 2070.99M |
| Intangible assets | 56.92M | 72.51M | 82.74M | 111.04M | 21.64M |
| Other current assets | 25.19M | 18.73M | 39.73M | 49.02M | 0.70M |
| Total liab | 611.11M | 661.39M | 568.19M | 803.04M | 503.61M |
| Total stockholder equity | 508.59M | 716.06M | 1097.15M | 1736.28M | 1505.37M |
| Deferred long term liab | - | - | - | 174.77M | 174.74M |
| Other current liab | 66.46M | 33.53M | 88.57M | 114.69M | 92.58M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.19M | 0.16M |
| Capital stock | 0.01M | 0.01M | 0.20M | 0.19M | 0.16M |
| Retained earnings | -6150.32M | -5837.56M | -5290.53M | -4397.66M | -2297.93M |
| Other liab | - | - | - | 216.83M | 346.57M |
| Good will | - | 0.00M | 49.24M | 60.21M | 21.31M |
| Other assets | 47.17M | 41.17M | 42.22M | 88.72M | 43.99M |
| Cash | 167.20M | 561.57M | 944.07M | 1315.79M | 1550.00M |
| Cash and equivalents | 167.20M | 561.57M | 944.07M | 1315.79M | 1550.00M |
| Total current liabilities | 95.97M | 107.27M | 163.86M | 172.96M | 134.76M |
| Current deferred revenue | 18.95M | 30.60M | 48.49M | 47.82M | 33.24M |
| Net debt | 249.88M | -93.84M | -704.76M | -902.54M | -1526.97M |
| Short term debt | 0.00M | 28.96M | 17.47M | 29.33M | 0.75M |
| Short long term debt total | 417.08M | 467.73M | 239.31M | 413.26M | 23.03M |
| Other stockholder equity | 6657.05M | 6555.42M | 6386.19M | 6133.75M | 3804.84M |
| Property plant equipment | 528.70M | 598.15M | 397.22M | 715.53M | 145.77M |
| Total current assets | 471.84M | 602.74M | 1001.75M | 1450.08M | 1723.05M |
| Long term investments | 14.88M | 48.47M | 77.91M | 113.73M | 102.04M |
| Net tangible assets | - | - | - | 1565.03M | 1462.41M |
| Short term investments | 255.42M | 0.00M | -0.65M | - | - |
| Net receivables | 24.03M | 22.44M | 17.90M | 80.91M | 149.90M |
| Inventory | - | - | 0.05M | 4.36M | 3.36M |
| Accounts payable | 10.57M | 14.17M | 9.32M | 10.45M | 8.19M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 62.01M |
| Accumulated other comprehensive income | 1.85M | -1.81M | 1.48M | -2.63M | -1.72M |
| Common stock total equity | - | - | - | 0.19M | 0.16M |
| Retained earnings total equity | - | - | - | -4397.66M | -2297.93M |
| Non currrent assets other | 47.17M | 55.34M | 58.71M | 202.46M | 43.99M |
| Non current assets total | 647.86M | 774.71M | 663.59M | 1089.24M | 347.94M |
| Capital lease obligations | 439.88M | 467.73M | 241.77M | 413.26M | 23.03M |
| Long term debt total | 0.00M | 0.03M | 0.48M | 0.00M | 22.28M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -233.25M | -62.24M | -4.28M | -67.39M | -5.00M |
| Change to liabilities | - | - | - | -50.45M | -12.74M |
| Total cashflows from investing activities | -240.29M | -62.24M | -80.69M | -67.39M | -73.26M |
| Net borrowings | -0.35M | -0.90M | -1.29M | 97.84M | -1.12M |
| Total cash from financing activities | 17.77M | -1.74M | -3.22M | 95.34M | 1534.14M |
| Change to operating activities | - | - | - | -44.93M | 65.93M |
| Net income | -312.76M | -547.03M | -892.87M | -2106.37M | -1836.64M |
| Change in cash | -393.18M | -383.84M | -380.00M | -223.35M | 1207.05M |
| Begin period cash flow | 567.41M | 989.58M | 1369.58M | 1592.93M | 385.88M |
| End period cash flow | 174.23M | 605.74M | 989.58M | 1369.58M | 1592.93M |
| Total cash from operating activities | -171.06M | -319.58M | -295.50M | -252.20M | -253.82M |
| Issuance of capital stock | 19.47M | 0.00M | 0.00M | 99.30M | 0.00M |
| Depreciation | 58.99M | 63.02M | 71.55M | 44.42M | 29.08M |
| Other cashflows from investing activities | 0.62M | 1.19M | -1.34M | -15.12M | -16.74M |
| Change to inventory | - | - | - | 0.16M | -0.63M |
| Change to account receivables | -1.47M | -4.72M | 50.07M | 55.02M | -114.09M |
| Sale purchase of stock | 19.47M | 0.08M | -0.02M | 99.54M | -25.00M |
| Other cashflows from financing activities | -1.34M | -0.92M | -1.90M | -2.73M | 1560.27M |
| Change to netincome | - | - | - | 1859.54M | 1608.69M |
| Capital expenditures | 7.67M | 62.54M | 40.80M | 52.27M | 56.52M |
| Change receivables | - | - | - | 55.02M | -114.09M |
| Cash flows other operating | - | - | - | -58.81M | -34.70M |
| Cash and cash equivalents changes | - | - | - | -224.25M | 1207.07M |
| Change in working capital | -44.09M | -89.67M | 29.84M | -37.01M | -61.54M |
| Stock based compensation | 81.55M | 112.34M | 229.88M | 1930.64M | 1606.02M |
| Other non cash items | 46.62M | 142.69M | 266.89M | -69.28M | -20.95M |
| Free cash flow | -178.72M | -382.13M | -336.30M | -304.47M | -310.34M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings |
2.04 18.10% |
13.31 | - | - | 2.90 | 0.97 | 3.01 | -1.79 |
| NVO Novo Nordisk A/S |
-0.52 1.33% |
38.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
9.39 1.80% |
530.42 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-0.93 0.11% |
815.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jason Kelly | Founder, CEO & Director | 1981 |
| Dr. Reshma P. Shetty | Founder, Pres, COO & Director | 1981 |
| Mr. Mark E. Dmytruk | Chief Financial Officer | 1971 |
| Mr. Thomas Knight Jr. | Founder | NA |
| Mr. Austin Che | Founder, Head of Strategy & Treasurer | NA |
| Mr. Bartholomew Canton | Founder, CTO & Sec. | NA |
| Marie E Fallon | Chief Accounting Officer | NA |
| Karen Tepichin | Gen. Counsel & Sec. | NA |
| Ms. Anna Marie Wagner | Sr. VP of Corp. Devel. | NA |
| Ms. Samantha Sutton | Head of People | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.80%
Consumer Cyclical
-0.28%
Consumer Defensive
-0.47%
Energy
+0.39%
Financial Services
-0.37%
Financials
-0.92%
Healthcare
+0.69%
Industrials
+0.14%
Real Estate
-0.41%
Technology
+0.14%
Utilities
-0.27%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...